VERMONT: Virtual Environment Rehabilitation for Patients With Motor Neglect Trial

Sponsor
Cambridge University Hospitals NHS Foundation Trust (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03887962
Collaborator
(none)
40
1
2
54
0.7

Study Details

Study Description

Brief Summary

Motor neglect describes a loss of function without a loss of strength, reflexes or sensation. Motor neglect has been described in patients with traumatic brain injury, stroke and chronic pain conditions, e.g. complex regional pain syndrome. These conditions affect hundreds of thousands of patients in the UK each year and motor neglect is a significant obstacle in their rehabilitation towards a good outcome. By focussing on improving motor neglect, outcomes including function and quality of life for these groups of patients may significantly improve.

Motor neglect is potentially reversible. Rehabilitation using repetition, feedback and motivation are beneficial for optimal outcome. Current protocols use face-to-face physical therapies which can not optimise intensity due to a lack of resources. Furthermore, engagement with exercise is recognised to be poor, in part, due to a lack of attention. Innovative technologies may well improve engagement. Furthermore, telemedicine, or remote delivery of healthcare, offer opportunities in resource management, which can be delivered through the use of such innovative technologies.

Virtual reality systems have been designed and utilised in rehabilitation in various conditions, e.g post-stroke, cerebral palsy and Parkinson's disease. Studies demonstrate improved function in both upper and lower limbs. Potentially more effective treatments for motor neglect utilising such technology are therefore available but need more formal evaluation.

This protocol describes a Phase II randomised controlled trial for both in-patients and out-patients requiring rehabilitation with motor neglect from neurological causes (stroke, traumatic brain injury) and chronic pain conditions (Complex Regional Pain Syndromes, chronic low back pain and referred leg pain (sciatica)). The intervention will be a novel interactive virtual reality system using established technology and tailored software used in conjunction with a treadmill. The control group will be the same screen showing random static images whilst on the treadmill. Rehabilitation for each group will be offered in 3-4 sessions per week for 2 weeks. Each session will last about 30 minutes supervised by a physiotherapist. Follow-up will be by questionnaire at weeks 2, 6 and 12 and by face-to-face consultation at weeks 2 and 12.

Condition or Disease Intervention/Treatment Phase
  • Device: Virtual Environment Biofeedback
  • Device: Treadmill walking with no Virtual Environment Biofeedback
N/A

Detailed Description

To investigate whether a virtual reality biofeedback system in conjunction with a treadmill is safe and feasible for the rehabilitation of patients with motor neglect due to chronic pain conditions, traumatic brain injury and stroke compared to a control group of patients with these conditions whose rehabilitation consists of a non-virtual reality screen and treadmill.

To investigate whether a virtual reality biofeedback system in conjunction with a treadmill can improve outcome such as distance walked, pain, function, emotional well being and activity.

Study Design Randomised single-blind controlled trial

Setting The study will take place as part of the normal rehabilitation programmes at the single centre of Addenbrookes's Hospital, Cambridge University Hospitals NHS Foundation Trust. The treadmill gait task will be undertaken in the Clinical Movement Laboratory in Clinic 9 (Orthotics and Prosthetics Department).

Study population Subjects will be recruited from patients attending in-patient and out-patient rehabilitation programmes for chronic pain conditions or neurological conditions. Suitable candidates will be identified by the consultants or therapists involved in the programme. With consent, potential subjects will be referred to the researchers for screening.

Inclusion criteria

  • Patients with a diagnosis of stroke (of any cause), traumatic brain injury or a chronic pain condition of more than 3 months duration (e.g. back and referred leg pain; complex regional pain syndrome; fibromyalgia) who are undergoing an inpatient or out-patient rehabilitation programme

  • Motor neglect as assessed by standard clinical examination by a physiotherapist trained to detect such motor neglect. This is defined as weakness and functional impairment without a loss of strength, reflexes or sensation.

Exclusion criteria

  • Patients with active serious medical problems that might affect their ability to participate in the exercise protocol (e.g. ongoing sepsis; recent myocardial infarction)

  • Patients who are unable to use treadmill safely as judged by the screening physiotherapist.

  • Patients who are unable to give informed consent, either through issues relating to competency or to language.

  • Patients with significant previous experience of virtual reality rehabilitation.

Sample size This will be calculated using standard models. It is unknown what the effect size will be. Alpha will be 0.05, Beta will be 0.2. It is likely that at least 20 patients will need to be recruited in each arm (40 in total). Estimating the likely recruitment target from the numbers of patients requiring inpatients rehabilitation at Addenbrooke's (n=400 per annum for stroke, traumatic brain injury, back pain and Complex Regional Pain Syndrome), this would require a 12-month window of recruitment, assuming approximately 10% successful enrolment (n=40).

Withdrawal criteria Patients who wish to withdraw will be allowed to do so with out this affecting their rehabilitation.

Randomisation Subjects will be randomised to either the study or control group using a concealed blind allocation. This will be performed by a group independent from the trial.

Subjects will be allocated to the study:control groups on a 1:1 ratio using a random number generator (e.g. www.mathgoodies.com/calculators/random_no_custom.html) to determine the order of the couplets.

The exception will be applied to the groups who are successfully screened (e.g. Back Pain Programme). For this purpose, the entire group will be randomised to either receiving control or intervention due to cross-contamination of the treatment effect within a single group receiving otherwise identical rehabilitation.

Blinding Patients and therapists can not be blinded due to the nature of the research. Data analysis will be conducted by members of the trial research group who are blinded to whether an individual patient received the experimental or control arm. This will be achieved by the use of data stripped of any patient identifiable content and divided into the two groups. This task will be performed by the senior physiotherapist supervising the project. There should be no necessity to 'unblind' subjects from the study due to the lack of any clear serious side effects associated with the intervention.

Intervention Patients will be randomly assigned to one of two groups: intervention or control.

Both groups will walk on a treadmill as part of the task. Walking on the treadmill will be explained and demonstrated, and the subjects will have time to practice this task before this study commences. For extra safety, the subjects will be allowed to use the handlebars of the treadmill for extra support if they wish. The therapy assistant will stand next to the Emergency stop button and is fully trained in the use of the treadmill and Virtual Environment device.

In both groups the walking cycles will be determined by their functional ability as assessed by the screening physiotherapist but the treadmill walking will not be longer than 5 minutes at each cycle. Every 30 seconds, the therapy assistant will ask whether the subject would like to change the speed of the treadmill and will make a decision based on his experience as to whether to increase the treadmill by 0.1 km/h or reduce / stop the treadmill as necessary. The next cycle will start at the speed at which the previous cycle finished. The next day's session will commence at baseline speed and increase or decrease as above. The subject will be required to complete five walking cycles and will have up to a 3 minute break between each cycle. The primary outcome will be the distance walked in the final 5-minute cycle of the session at Baseline, week 2 and at 24 weeks. This task will be performed 3 to 4 times per week for two weeks. The speed of each cycle will be set back to baseline for each day.

Intervention group:

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomised single-blind controlled trialRandomised single-blind controlled trial
Masking:
Single (Outcomes Assessor)
Masking Description:
Data collected by unblended participant and research assistant. Outcomes analysed by blinded team and statistician Objective machine outcomes are blinded
Primary Purpose:
Treatment
Official Title:
Trial of Virtual Reality Biofeedback in Patients With Motor Neglect From Chronic Pain or Cerebrovascular Disease
Actual Study Start Date :
May 1, 2017
Anticipated Primary Completion Date :
Jul 1, 2021
Anticipated Study Completion Date :
Nov 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Virtual Environment feedback

Subjects will be instructed to walk on a treadmill, moving at a constant speed, following a "virtual path" displayed on a flat screen in front of them. In this group, the gait task may involve avoiding virtual obstacles on the screen in the path or stepping on targets as determined by the therapist.

Device: Virtual Environment Biofeedback
Treadmill walking. Modified available technology for gait capture. Tailored software for virtual environment rendering and immersive qualities
Other Names:
  • Real time biofeedback
  • Active Comparator: Control

    Subjects will be instructed to walk on a treadmill, moving at a constant speed. The flat screen will play random scenes from the virtual reality environment and thus control for attentional and non-movement related clues.

    Device: Treadmill walking with no Virtual Environment Biofeedback
    Treadmill walking. Flat screen / no virtual environment to act as attentional control.
    Other Names:
  • Control group
  • Outcome Measures

    Primary Outcome Measures

    1. Distance walked (machine-reported) [Week 2]

      Distance walked in 5 minutes at weeks 2 compared to baseline (% change)

    2. Lower Extremity Functional Index [Week 2]

      Self-reported 20-question Functional Activity Questionnaire with minimal clinically important difference of 9 (range 0-80). Each question scored 0-4. Low scores indicate less function.

    3. Lower Extremity Functional Index [Week 24]

      Self-reported 20-question Functional Activity Questionnaire with minimal clinically important difference of 9 (range 0-80). Each question scored 0-4. Low scores indicate less function.

    Secondary Outcome Measures

    1. Brief Pain Inventory [Weeks 2,12,24]

      Self-reported questionnaire - mean score (11-point analogue scale). High scores indicate more pain. % change from baseline will be calculated

    2. Human Activity Profile [Weeks 2,12,24]

      Self-reported questionnaire (0-94 points). Low scores indicate loss of function.

    3. Hospital Anxiety and Depression Scale [Weeks 2,12,24]

      Self-reported questionnaire (0-21 on each dimension of Anxiety and Depression). High scores indicate high Anxiety or Depression

    4. Neglect Like Symptom Questionnaire [Weeks 2,12,24]

      Self-reported questionnaire (1-6). High scores indicate more Neglect-like symptoms

    5. Satisfaction questionnaire [Weeks 2, 24]

      Self-reported questionnaire. 0-5 score. High scores indicate high satisfaction

    6. Machine-reported average stride length [Week 2]

      Average stride length (cm)

    7. Machine-reported number of steps [Week 2]

      Number of steps (whole number)

    8. Machine-reported gait symmetry [Week 2]

      Asymmetry (left-right split presented in numerical form)

    9. Machine-reported gait timing [Week 2]

      Timing (Proportion of gait with planted foot and raised foot measured as %).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Patients with a diagnosis of stroke (of any cause), traumatic brain injury or chronic pain condition of more than 3 months duration (e.g. back and referred leg pain; complex regional pain syndrome; fibromyalgia) who are undergoing an inpatient or out-patient rehabilitation programme

    • Motor neglect as assessed by standard clinical examination by a physiotherapist trained to detect such motor neglect (EV). This is defined as weakness and functional impairment without a loss of strength, reflexes or sensation.

    Exclusion Criteria:
    • Patients with active serious medical problems that might affect their ability to participate in the exercise protocol (e.g. ongoing sepsis; recent myocardial infarction)

    • Patients who are unable to use treadmill safely as judged by the screening physiotherapist (EV).

    • Patients who are unable to give informed consent, either through issues relating to competency or to language.

    • Patients with significant previous experience of virtual reality rehabilitation.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cambridge University Hospitals NHS Foundation Trust Cambridge Cambridgeshire United Kingdom CB2 0QQ

    Sponsors and Collaborators

    • Cambridge University Hospitals NHS Foundation Trust

    Investigators

    • Principal Investigator: Nicholas GN Shenker, MD, Cambridge University Hospitals NHS Foundation Trust

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Dr Nicholas Shenker, Consultant Rheumatologist, Cambridge University Hospitals NHS Foundation Trust
    ClinicalTrials.gov Identifier:
    NCT03887962
    Other Study ID Numbers:
    • A092932
    • 17/LO/0299
    • 74696
    First Posted:
    Mar 25, 2019
    Last Update Posted:
    Jan 13, 2021
    Last Verified:
    Jan 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Dr Nicholas Shenker, Consultant Rheumatologist, Cambridge University Hospitals NHS Foundation Trust
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 13, 2021